Substratification of stage T1c prostate cancer based on the probability of biochemical recurrence

Matthew B Gretzer, Jonathan I. Epstein, Charles R. Pound, Patrick C. Walsh, Alan W. Partin

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objectives. To evaluate the influence of preoperative prostate-specific antigen (PSA), biopsy Gleason sum, and prostate biopsy quantitative histologic findings on the probability of biochemical failure in an attempt to identify criteria to substratify Stage T1c prostate cancer more accurately. Methods. We reviewed the records of 1149 patients who underwent prostatectomy for T1c disease between 1988 and 2000. Biochemical recurrence (PSA 0.2 ng/mL or greater) defined the endpoint in this study. Recursive partitioning analysis was used to establish cutpoints for preoperative PSA level, biopsy Gleason sum, number of positive biopsy cores, and maximal percentage of any single biopsy core involved with cancer. These cutoff values were then evaluated using Kaplan-Meier estimations to determine the probability of remaining biochemically recurrence free. Results. Using a PSA cutpoint of 10 ng/mL or a biopsy Gleason sum of 7, two groups of patients were identified (T1cI and T1cII). The rate of freedom from PSA recurrence at 3, 5, and 10 years after surgery for T1cI was 98%, 96%, and 96%, respectively, and for T1cII was 86%, 83%, and 73%, respectively (P <0.001). For T1cII patients, the greatest percentage of cancer in a single biopsy core was found to be a predictor of biochemical failure on multivariate analysis and, using a cutoff value of 50%, further stratified the PSA recurrence-free rates for the men in group T1cII (90% and 85% versus 75% and 56% at 5 and 10 years after surgery, respectively, P = 0.03). Conclusions. The results of this study demonstrate that within Stage T1c there are two populations of patients with significantly different recurrence probabilities: T1cI (Gleason sum less than 7 and PSA 10 ng/mL or less) and T1cII (Gleason sum 7 or greater or PSA greater than 10 ng/mL). Furthermore, using a cutpoint of 50% of cancer in a single core of biopsy tissue, additional risk stratification is afforded to men with higher risk "T1cII" cancer.

Original languageEnglish (US)
Pages (from-to)1034-1039
Number of pages6
JournalUrology
Volume60
Issue number6
DOIs
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Biopsy
Recurrence
Neoplasms
Prostatectomy
Prostate
Multivariate Analysis
Population

ASJC Scopus subject areas

  • Urology

Cite this

Substratification of stage T1c prostate cancer based on the probability of biochemical recurrence. / Gretzer, Matthew B; Epstein, Jonathan I.; Pound, Charles R.; Walsh, Patrick C.; Partin, Alan W.

In: Urology, Vol. 60, No. 6, 01.12.2002, p. 1034-1039.

Research output: Contribution to journalArticle

Gretzer, Matthew B ; Epstein, Jonathan I. ; Pound, Charles R. ; Walsh, Patrick C. ; Partin, Alan W. / Substratification of stage T1c prostate cancer based on the probability of biochemical recurrence. In: Urology. 2002 ; Vol. 60, No. 6. pp. 1034-1039.
@article{e9c82ff135bb4027a393473907e83424,
title = "Substratification of stage T1c prostate cancer based on the probability of biochemical recurrence",
abstract = "Objectives. To evaluate the influence of preoperative prostate-specific antigen (PSA), biopsy Gleason sum, and prostate biopsy quantitative histologic findings on the probability of biochemical failure in an attempt to identify criteria to substratify Stage T1c prostate cancer more accurately. Methods. We reviewed the records of 1149 patients who underwent prostatectomy for T1c disease between 1988 and 2000. Biochemical recurrence (PSA 0.2 ng/mL or greater) defined the endpoint in this study. Recursive partitioning analysis was used to establish cutpoints for preoperative PSA level, biopsy Gleason sum, number of positive biopsy cores, and maximal percentage of any single biopsy core involved with cancer. These cutoff values were then evaluated using Kaplan-Meier estimations to determine the probability of remaining biochemically recurrence free. Results. Using a PSA cutpoint of 10 ng/mL or a biopsy Gleason sum of 7, two groups of patients were identified (T1cI and T1cII). The rate of freedom from PSA recurrence at 3, 5, and 10 years after surgery for T1cI was 98{\%}, 96{\%}, and 96{\%}, respectively, and for T1cII was 86{\%}, 83{\%}, and 73{\%}, respectively (P <0.001). For T1cII patients, the greatest percentage of cancer in a single biopsy core was found to be a predictor of biochemical failure on multivariate analysis and, using a cutoff value of 50{\%}, further stratified the PSA recurrence-free rates for the men in group T1cII (90{\%} and 85{\%} versus 75{\%} and 56{\%} at 5 and 10 years after surgery, respectively, P = 0.03). Conclusions. The results of this study demonstrate that within Stage T1c there are two populations of patients with significantly different recurrence probabilities: T1cI (Gleason sum less than 7 and PSA 10 ng/mL or less) and T1cII (Gleason sum 7 or greater or PSA greater than 10 ng/mL). Furthermore, using a cutpoint of 50{\%} of cancer in a single core of biopsy tissue, additional risk stratification is afforded to men with higher risk {"}T1cII{"} cancer.",
author = "Gretzer, {Matthew B} and Epstein, {Jonathan I.} and Pound, {Charles R.} and Walsh, {Patrick C.} and Partin, {Alan W.}",
year = "2002",
month = "12",
day = "1",
doi = "10.1016/S0090-4295(02)01997-0",
language = "English (US)",
volume = "60",
pages = "1034--1039",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Substratification of stage T1c prostate cancer based on the probability of biochemical recurrence

AU - Gretzer, Matthew B

AU - Epstein, Jonathan I.

AU - Pound, Charles R.

AU - Walsh, Patrick C.

AU - Partin, Alan W.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Objectives. To evaluate the influence of preoperative prostate-specific antigen (PSA), biopsy Gleason sum, and prostate biopsy quantitative histologic findings on the probability of biochemical failure in an attempt to identify criteria to substratify Stage T1c prostate cancer more accurately. Methods. We reviewed the records of 1149 patients who underwent prostatectomy for T1c disease between 1988 and 2000. Biochemical recurrence (PSA 0.2 ng/mL or greater) defined the endpoint in this study. Recursive partitioning analysis was used to establish cutpoints for preoperative PSA level, biopsy Gleason sum, number of positive biopsy cores, and maximal percentage of any single biopsy core involved with cancer. These cutoff values were then evaluated using Kaplan-Meier estimations to determine the probability of remaining biochemically recurrence free. Results. Using a PSA cutpoint of 10 ng/mL or a biopsy Gleason sum of 7, two groups of patients were identified (T1cI and T1cII). The rate of freedom from PSA recurrence at 3, 5, and 10 years after surgery for T1cI was 98%, 96%, and 96%, respectively, and for T1cII was 86%, 83%, and 73%, respectively (P <0.001). For T1cII patients, the greatest percentage of cancer in a single biopsy core was found to be a predictor of biochemical failure on multivariate analysis and, using a cutoff value of 50%, further stratified the PSA recurrence-free rates for the men in group T1cII (90% and 85% versus 75% and 56% at 5 and 10 years after surgery, respectively, P = 0.03). Conclusions. The results of this study demonstrate that within Stage T1c there are two populations of patients with significantly different recurrence probabilities: T1cI (Gleason sum less than 7 and PSA 10 ng/mL or less) and T1cII (Gleason sum 7 or greater or PSA greater than 10 ng/mL). Furthermore, using a cutpoint of 50% of cancer in a single core of biopsy tissue, additional risk stratification is afforded to men with higher risk "T1cII" cancer.

AB - Objectives. To evaluate the influence of preoperative prostate-specific antigen (PSA), biopsy Gleason sum, and prostate biopsy quantitative histologic findings on the probability of biochemical failure in an attempt to identify criteria to substratify Stage T1c prostate cancer more accurately. Methods. We reviewed the records of 1149 patients who underwent prostatectomy for T1c disease between 1988 and 2000. Biochemical recurrence (PSA 0.2 ng/mL or greater) defined the endpoint in this study. Recursive partitioning analysis was used to establish cutpoints for preoperative PSA level, biopsy Gleason sum, number of positive biopsy cores, and maximal percentage of any single biopsy core involved with cancer. These cutoff values were then evaluated using Kaplan-Meier estimations to determine the probability of remaining biochemically recurrence free. Results. Using a PSA cutpoint of 10 ng/mL or a biopsy Gleason sum of 7, two groups of patients were identified (T1cI and T1cII). The rate of freedom from PSA recurrence at 3, 5, and 10 years after surgery for T1cI was 98%, 96%, and 96%, respectively, and for T1cII was 86%, 83%, and 73%, respectively (P <0.001). For T1cII patients, the greatest percentage of cancer in a single biopsy core was found to be a predictor of biochemical failure on multivariate analysis and, using a cutoff value of 50%, further stratified the PSA recurrence-free rates for the men in group T1cII (90% and 85% versus 75% and 56% at 5 and 10 years after surgery, respectively, P = 0.03). Conclusions. The results of this study demonstrate that within Stage T1c there are two populations of patients with significantly different recurrence probabilities: T1cI (Gleason sum less than 7 and PSA 10 ng/mL or less) and T1cII (Gleason sum 7 or greater or PSA greater than 10 ng/mL). Furthermore, using a cutpoint of 50% of cancer in a single core of biopsy tissue, additional risk stratification is afforded to men with higher risk "T1cII" cancer.

UR - http://www.scopus.com/inward/record.url?scp=0036900782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036900782&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(02)01997-0

DO - 10.1016/S0090-4295(02)01997-0

M3 - Article

VL - 60

SP - 1034

EP - 1039

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -